Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia.

The newly developed immune-related gene signature is an effective biomarker for predicting prognosis in AML and provides a basis, from an immunological perspective, for the development of comprehensive therapeutic strategies.